Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q2 2025
Institutional positions in Immunovant, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 169
- −24 vs. Q1 2025
- Shares held
- 96.2M
- +1.48M (+1.6%) vs. Q1 2025
- Total value
- $1.54B
- −$79.8M (−4.9%) vs. Q1 2025
- New holders
- 24
- 73 more added
- Sold out
- 48
- 48 more reduced
1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMVT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 226 | $4.25B |
| Q1 2026 | 216 | $2.75B |
| Q4 2025 | 197 | $2.76B |
| Q3 2025 | 186 | $1.53B |
| Q2 2025 | 169 | $1.54B |
| Q1 2025 | 194 | $1.62B |
| Q4 2024 | 187 | $1.98B |
| Q3 2024 | 182 | $2.26B |
| Q2 2024 | 197 | $1.97B |
| Q1 2024 | 209 | $2.27B |
| Q4 2023 | 228 | $2.88B |
| Q3 2023 | 181 | $2.57B |
| Q2 2023 | 147 | $1.05B |
| Q1 2023 | 142 | $903.7M |
| Q4 2022 | 133 | $1.00B |
| Q3 2022 | 112 | $238.1M |
| Q2 2022 | 94 | $156.5M |
| Q1 2022 | 112 | $218.6M |
| Q4 2021 | 118 | $322.4M |
| Q3 2021 | 119 | $293.6M |
| Q2 2021 | 110 | $407.5M |
| Q1 2021 | 120 | $654.3M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Immunovant, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Emerald Advisers, LLC | 0 | $0 | 0.00% | −9,246−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −4,416−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −3,923−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −2,593−100.0% | Sold out |
| BI Asset Management Fondsmaeglerselskab A/S | 0 | $0 | 0.00% | −2,181−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −1,600−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −649−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −515−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −158−100.0% | Sold out |
| Sierra Ocean, LLC | 0 | $0 | 0.00% | −97−100.0% | Sold out |
| Synergy Investment Management, LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| South State Corp. | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |